Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $21.38 Average Target Price from Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have earned an average rating of “Moderate Buy” from the thirteen brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $21.3750.

Several analysts have recently issued reports on KROS shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday. Oppenheimer reiterated an “outperform” rating and issued a $27.00 target price (up previously from $23.00) on shares of Keros Therapeutics in a report on Wednesday, November 12th. Zacks Research upgraded Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. Wedbush lifted their price objective on Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, November 6th. Finally, Bank of America boosted their target price on Keros Therapeutics from $18.00 to $19.00 and gave the stock a “neutral” rating in a report on Friday, November 28th.

Insider Activity at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $95,659,436.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the firm’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $84,975,125.25. The disclosure for this sale is available in the SEC filing. 22.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. ADAR1 Capital Management LLC grew its stake in shares of Keros Therapeutics by 6,294.5% in the first quarter. ADAR1 Capital Management LLC now owns 1,486,461 shares of the company’s stock valued at $15,147,000 after buying an additional 1,463,215 shares in the last quarter. Western Standard LLC lifted its position in Keros Therapeutics by 42.7% during the 3rd quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock worth $34,644,000 after acquiring an additional 654,989 shares in the last quarter. DRW Securities LLC purchased a new position in Keros Therapeutics in the 1st quarter worth approximately $4,737,000. Canada Pension Plan Investment Board acquired a new stake in Keros Therapeutics in the second quarter valued at approximately $4,251,000. Finally, Caption Management LLC grew its position in Keros Therapeutics by 114.1% in the second quarter. Caption Management LLC now owns 36,078 shares of the company’s stock valued at $482,000 after acquiring an additional 291,997 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Price Performance

NASDAQ KROS opened at $20.27 on Friday. Keros Therapeutics has a 12 month low of $9.12 and a 12 month high of $22.55. The company has a 50-day moving average of $18.27 and a 200-day moving average of $15.96. The company has a market cap of $617.63 million, a P/E ratio of 13.16, a P/E/G ratio of 0.25 and a beta of 0.89.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.93. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%. The business had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $4.22 million. During the same period last year, the company earned ($1.41) earnings per share. The company’s quarterly revenue was up 3585.6% on a year-over-year basis. As a group, equities research analysts anticipate that Keros Therapeutics will post -4.74 EPS for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.